Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
troriluzole
- Development stage
- Phase 3
- Lead developer
- Biohaven
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Troriluzole is a third-generation novel prodrug and new chemical entity that acts as a glutamate modulator. It is designed to reduce synaptic levels of glutamate by increasing its uptake from the synapse and decreasing presynaptic release. This mechanism targets excessive glutamatergic activity implicated in neurodegenerative diseases such as spinocerebellar ataxia (SCA), Alzheimer's disease, obsessive-compulsive disorder (OCD), and others. Troriluzole is a tripeptide prodrug of riluzole with improved bioavailability and once-daily oral dosing. Developed primarily by Biohaven Pharmaceuticals, it has shown significant efficacy in slowing disease progression in SCA patients by 50–70% over three years[1][2][4][6].
- Brand names
- Dazluma
- Other names
- trigriluzoleTroriluzole-hydrochloride
02
Targets
EAAT3 (Excitatory amino acid transporter 3)
Beyond the preview
Go deeper on troriluzole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on troriluzole.